JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

19.16 -11.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.95

Максимум

19.69

Ключови измерители
By Trading Economics
Приходи	-7.3M -68M
Продажби	23M 68M
Марж на печалбата	-99.318
Служители	298
EBITDA	42M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+107.01% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	123M 1.9B
Предишно отваряне	30.17
Предишно затваряне	19.16

Настроения в новините

By Acuity

81%

19%

326 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1.05.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1.05.2026 г., 18:37 ч. UTC

Значими двигатели на пазара

Senseonic Shares Slide on Underwritten Offering Price

1.05.2026 г., 16:46 ч. UTC

Значими двигатели на пазара

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2.05.2026 г., 19:57 ч. UTC

Придобивния, сливания и поглъщания

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2.05.2026 г., 15:24 ч. UTC

Печалби

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2.05.2026 г., 12:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 20:42 ч. UTC

Печалби

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1.05.2026 г., 19:18 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1.05.2026 г., 19:13 ч. UTC

Пазарно говорене

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1.05.2026 г., 18:36 ч. UTC

Печалби

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1.05.2026 г., 18:35 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1.05.2026 г., 18:28 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1.05.2026 г., 18:27 ч. UTC

Пазарно говорене

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1.05.2026 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Barclays Completes Acquisition of Best Egg

1.05.2026 г., 18:04 ч. UTC

Печалби

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1.05.2026 г., 17:43 ч. UTC

Пазарно говорене

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1.05.2026 г., 17:37 ч. UTC

Пазарно говорене

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1.05.2026 г., 17:30 ч. UTC

Пазарно говорене

Печалби

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1.05.2026 г., 17:28 ч. UTC

Пазарно говорене

Печалби

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Печалби

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1.05.2026 г., 17:19 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1.05.2026 г., 16:38 ч. UTC

Пазарно говорене

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1.05.2026 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

107.01% нагоре

12-месечна прогноза

Среден 39.56 USD 107.01%

Висок 57 USD

Нисък 29 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

326 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.